VA's $1.05B Pharmaceutical Prime Vendor Contract Awarded to McKesson Corporation for April 2025

Contract Overview

Contract Amount: $1,045,889,952 ($1.0B)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2025-04-01

End Date: 2025-04-30

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 APRIL

Plain-Language Summary

Department of Veterans Affairs obligated $1.05 billion to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 APRIL Key points: 1. The Department of Veterans Affairs (VA) awarded a significant contract for pharmaceutical prime vendor services. 2. McKesson Corporation, a major player in pharmaceutical distribution, secured the award. 3. The contract value for April 2025 is substantial, indicating a critical need for these services. 4. This award highlights the ongoing reliance on large distributors for essential medical supplies within the federal government.

Value Assessment

Rating: good

The contract value of $1.05 billion for a single month is high, but typical for large-scale pharmaceutical distribution. Benchmarking against previous PPV contracts and industry standards is necessary for a precise value assessment.

Cost Per Unit: N/A

Competition Analysis

Competition Level: unknown

The contract type is a delivery order, suggesting it may be part of a larger indefinite-delivery/indefinite-quantity (IDIQ) contract. The method of competition (full and open, limited, or sole-source) is not specified, impacting price discovery.

Taxpayer Impact: The efficient distribution of pharmaceuticals is crucial for veteran healthcare. The cost-effectiveness of this award directly impacts taxpayer funds allocated to the VA's medical services.

Public Impact

Ensures timely access to a wide range of pharmaceuticals for veterans. Supports the VA's mission to provide comprehensive healthcare services. Maintains the supply chain integrity for critical medications. Potentially impacts drug pricing and availability for other federal agencies if part of a larger shared contract.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

  • Lack of clarity on competition method.
  • Potential for price fluctuations in pharmaceutical markets.
  • Dependence on a single vendor for a critical supply chain.

Positive Signals

  • Award to an established and experienced vendor.
  • Ensures continuity of pharmaceutical supply for veterans.
  • Significant contract value indicates robust demand and service provision.

Sector Analysis

The healthcare sector, particularly pharmaceutical distribution, is characterized by high volume and complex logistics. Federal contracts in this area often involve large sums due to the scale of government healthcare operations and the critical nature of the products.

Small Business Impact

The Pharmaceutical Prime Vendor program typically relies on large, established distributors. Opportunities for small businesses may exist further down the supply chain as subcontractors, but direct prime contract awards are less common.

Oversight & Accountability

Oversight will focus on McKesson's performance in meeting delivery schedules, maintaining drug quality, and adhering to contract terms. The VA's contracting officers will monitor compliance and manage any disputes.

Related Government Programs

  • Department of Veterans Affairs Contracting
  • Department of Veterans Affairs Programs

Risk Flags

  • Potential for price increases due to market volatility.
  • Dependence on a single vendor for critical supplies.
  • Risk of supply chain disruptions (e.g., manufacturing issues, transportation delays).
  • Ensuring compliance with all VA regulations and quality standards.

Tags

department-of-veterans-affairs, delivery-order, billion-dollar

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $1.05 billion to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 APRIL

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $1.05 billion.

What is the period of performance?

Start: 2025-04-01. End: 2025-04-30.

What was the specific competition method used for this delivery order, and how did it influence the final price?

The provided data does not specify the competition method (e.g., full and open, limited, sole-source). If it was sole-source or limited, price discovery might be less robust than in a full and open competition. Understanding this is key to assessing value for money and ensuring fair pricing for taxpayers.

How does McKesson's pricing for this contract compare to benchmarks for similar pharmaceutical distribution services provided to other large federal agencies or private healthcare systems?

Benchmarking McKesson's pricing against comparable contracts is essential for evaluating value. Without this comparison, it's difficult to definitively assess if the $1.05 billion monthly cost is competitive or if potential savings exist through alternative sourcing or negotiation strategies.

What mechanisms are in place to ensure the effectiveness and reliability of McKesson's pharmaceutical supply chain under this contract, particularly in light of potential disruptions?

Effectiveness relies on robust supply chain management, contingency planning, and performance metrics. The VA likely has quality assurance surveillance plans (QASPs) and performance standards to monitor McKesson's ability to consistently deliver pharmaceuticals, manage inventory, and respond to demand fluctuations.

More Contracts from Mckesson Corporation

View all Mckesson Corporation federal contracts →

Other Department of Veterans Affairs Contracts

View all Department of Veterans Affairs contracts →

Explore Related Government Spending